Abvc Biopharma (ABVC) Amortizatization of Intangibles (2024 - 2026)
Abvc Biopharma's (ABVC) quarterly Amortizatization of Intangibles came in at $82979.0 in Q2 2026, up 11.93% on a YoY basis from $74135.0 in Q2 2025, and down 3.93% quarter-over-quarter from $86373.0 in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Amortizatization of Intangibles for 3 consecutive years, with $82979.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Amortizatization of Intangibles rose 11.93% year-over-year to $82979.0; the trailing twelve-month figure through Jun 2026 stood at $467794.0 (up 216.77% YoY), and the FY2025 full-year result was $479504.0, up 183.9% from the prior year.
- Amortizatization of Intangibles slipped to $82979.0 in Q2 2026 per ABVC's latest filing, from $86373.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $208252.0 in Q4 2025 and bottomed at -$132728.0 in Q4 2024.
- Historically, Amortizatization of Intangibles has averaged $81775.2 across 3 years, with a median of $94766.0 in 2024.
- The widest YoY moves for Amortizatization of Intangibles: up 256.9% in 2025, down 26.61% in 2025.
- Over 3 years, Amortizatization of Intangibles stood at -$132728.0 in 2024, then soared by 256.9% to $208252.0 in 2025, then slumped by 60.15% to $82979.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $82979.0, $86373.0, and $208252.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 1.39 Mn |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | 82,979.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 82,979.00 |
| Mar 31, 2026 | 86,373.00 |
| Dec 31, 2025 | 208,252.00 |
| Sep 30, 2025 | 90,190.00 |
| Jun 30, 2025 | 74,135.00 |
| Mar 31, 2025 | 106,927.00 |
| Dec 31, 2024 | -132,728.00 |
| Sep 30, 2024 | 99,342.00 |
| Jun 30, 2024 | 101,022.00 |
| Mar 31, 2024 | 101,260.00 |